Spike with my growth for twenty years
Release time:
2020-08-14
Peak Accompanied My Growth for 20 Years
■ Xu Junxiong
, a pharmaceutical sales company, has been working for 20 years. Recall the bits and pieces of the past, only to find that the original time can carry all the memories, like a video disc, clearly recorded those sour or sweet moments, scene by scene, slowly presented in the brain. Memories of the past, taste the past, evoke some deep in the heart of the aftertaste. In the year of
, I graduated from the health school and went to the society. I was lucky to join Jianfeng Group, the largest and most famous enterprise in Jinhua. After a period of internship in the group clinic, the company arranged me to work in the infirmary of the cable company. "No, I'm the only one in the infirmary." I felt scared, can I do it well? can I do it well? "if you can do it well, just do it with your heart. if you don't understand something, you should ask more questions and consult more." Tang Huamei, head of the group's medical office, encouraged me to say. Although I was not sure, I decided to try hard, because from then on, I had a formal job and didn't have to ask for money from my family to support myself. I was an adult. After arriving at the cable company, I was responsible for the health management of more than 200 people in the whole factory. in addition to working hard, I also used the weekend break to study with the teachers in Jinhua hospital of traditional Chinese medicine. My efforts were recognized by my colleagues and quickly integrated into this big family.
years passed quickly, and I set myself a "great" goal: to take root in Jinhua and buy a two-bedroom apartment of 60 square meters! But the problem is that this goal is difficult to achieve if you rely on the death salary of the infirmary. Just at the beginning of 2001 , Jianfeng Pharmaceutical recruited salesmen for the company, "more work, more pay, no ceiling". I thought for a long time and finally made up my mind to make a dash. Through interviews and training, I successfully became a medical representative of the new special drug company.
To be honest, at that time I could say nothing but youth and passion. Fortunately, newborn calves are not afraid of tigers. As long as they lock in their customers, no matter how high the other party's position is, they will visit them first. Of course, it was always not smooth at first. I was well prepared. Facing the serious face of the other party, I was so nervous that I wanted to leave immediately. At such times, I secretly warn myself to be calm and calm. I am here to recommend good products. I will be turned away in a big deal. If I can't, I will find another department. Someone will always recognize you. This is repeated over and over again, coupled with the guidance of senior brothers and sisters, I slowly grew up, more and more customers recognized me and liked me, and my performance began to show. In those years, I used to be the first in the whole team in terms of sales volume of single hospital products and the first in the whole team in terms of sales volume generated by full coverage of single hospital products. It's hard to run business in the wind and rain, and stay away from my family. Of course, it's hard, but in the constant efforts, I grow up and mature. My house is spacious, my wife is beautiful, my children are lovely, and my happiness index can be imagined.
One day in August, 2011 9 , the leader suddenly talked to me and said that he was going to let me be the assistant to the general manager of Jianfeng Pharmaceutical Sales Company, responsible for the terminal sales in Zhejiang region. The news came so suddenly that I had never learned management and was at a loss. Can I do it? Can I do it? After consulting in many ways and thinking for three days and three nights, I finally made a decision to return to the company to take office.
The new position has new responsibilities, and the change of roles means that the problem must be considered more comprehensively and pay more attention to the overall situation, and the interests of team members must be taken into account while creating performance and profits. Because I have been in the marketing front line for many years, I know the hard work and ideas of the salesmen, as well as their difficulties and hopes for the company. I can think of others in management and strive for a win-win situation between the enterprise and the individual. Over the past few years, the general environment has been beset with difficulties, and the unit price of drug sales has been falling all the way. However, our terminal sales have been able to increase at a 25% rate every year, from no profit in 2012 to turning losses into profits, to an estimated profit of more than 3 million yuan this year.
Over the past 20 years, inspired by the enterprise spirit of "unity and struggle, truth-seeking and innovation, determination to rise to the top, and eternal climbing to the top", I have grown up under the care and care of leaders at all levels of the peak, and have made continuous progress with the support and help of all colleagues. In addition to serving as the executive deputy general manager of the pharmaceutical sales company, I have also obtained a licensed pharmacist certificate and become a member of Zhejiang Pharmaceutical Association, through the self-study examination to obtain a bachelor's degree in business management, self-worth has been continuously realized. Over the past 20 years, I have witnessed the growth of the peak year by year and the continuous record of performance. I am very proud to think that these achievements also have their own modest strength, and I am happy to work in such a company.
I grew up in the peak. The peak is wonderful because of the efforts of our peak people. I naturally blend with the peak and cannot be separated. As a peak person, I will continue to self-study, self-improvement, self-improvement, conscientious, excellence to do their job. I believe that with the unremitting struggle of all our peak people, the peak will move towards a higher development dimension and stand at the peak of the industry.
More information
Two Cement Enterprises Prosperous Production and Sales in May
With the gradual easing of the new crown epidemic, all over the project has started, Hubei, Yunnan two provinces cement market continued to improve, Daye peak cement company, Yunnan peak cement company two enterprises have recently shown a good momentum of production and sales. In May, the sales volume of Yunnan Jianfeng cement continued to rise. As of the time of publication, the average daily shipment volume reached more than 7400 tons, and the highest daily shipment volume reached more than 8700 tons, and the production capacity was fully released. Over the past few days, Yunnan Peak Packaging System has made great efforts to overcome the impact of narrow distribution sites and many cement varieties to ensure the completion of delivery tasks with good quality and quantity every day. In order to further balance production and sales and create conditions for the homogenization of cement delivered from the factory, Yunnan peak packaging system puts forward work requirements for relevant posts, emphasizes equipment inspection and process inspection during production, strictly implements safety operation procedures, and maintains safe and efficient operation of the system. Due to the impact of the new crown epidemic, Hubei cement market started late, Wuhan market is the hardest hit area, the current project construction is still not fully started, the volume pressure is greater. For this reason, daye peak departments cooperate closely, increase market development efforts, develop new mixing stations, focus on increasing the bulk share of Xianning, Huanggang and Wuhan markets, seize the opportunity of fine weather, and achieve the goal of rapid output. Internally, on the basis of equipment technical renovation and production capacity improvement, the delivery is effectively guaranteed, and the daily delivery capacity can basically be maintained at 10,000 tons. In May, Daye Peak sold more than 300000 tons of cement, an increase of 20% over the same period last year, with an average daily sales volume of more than 9900 tons, the highest in the current period since Daye Peak was put into production.
2020
07-31
The company's "safe production month" activities are about to start
June 2020 is the 19th national "safe production month", the theme of the activity is "eliminating hidden dangers of accidents and building a strong line of defense". A few days ago, the group company issued a notice to arrange the activities related to the organization of "safe production month" and put forward requirements. According to the group's "safe production month" activity plan, different key thematic activities will be held in the four weeks of June. The first week is the "Publicity and Safety Education Week", which focuses on the use of WeChat groups, electronic screens, publicity boards, banners, slogans and other forms for safety publicity, and organizes the study of national safety regulations, company safety system specifications and accident-free factory creation standards, Organize to watch safety warning education films, learn accident cases, etc., and improve employees' safety awareness by creating a safety atmosphere and organizing learning activities. The focus of the activities in the second week is "looking for potential sources of danger around you". Each unit takes departments and teams as units to investigate and analyze the potential risk factors in the process of daily production, maintenance and operation, find out the hazard sources that have not been included in the scope of risk point control, and report to the safety management department of the unit to form a risk assessment report, put forward solutions or suggestions, and supervise the implementation of rectification and timely eliminate potential safety hazards. The third week is the "on-site safety innovation achievements exhibition week", which focuses on the achievements of each unit in on-site safety management and on-site safety facilities in the past year, which are displayed in the form of pictures and texts through beautiful articles and wechat, so as to learn from each other and promote common progress. The fourth week is the "safety training and drill week", and the group company organizes the standardization of safety production and the elimination of hidden dangers.
2020
07-31
Jianfeng Pharmaceuticals ranks among the top 50 creative enterprises in Jinhua
News from our newspaper April 26 is World Intellectual Property Day. Jinhua City released the list of "Top 50 Creative Enterprises" for the first time. Jianfeng Pharmaceutical Company entered the list and ranked second among the enterprises in Jinhua Development Zone. The selection of creative enterprises, the enterprise holds the effective invention patent as the main indicator. Over the years, Jianfeng Pharmaceutical Co., Ltd. has taken "intellectual property rights help enterprise development, and scientific and technological innovation creates a century-old peak" as the company's intellectual property policy. It has actively cooperated with China Pharmaceutical University, Sichuan Institute of Antibiotic Industry, Zhejiang University of Technology, Xiamen University and other units to build a scientific research and innovation platform integrating production, learning and research, and flexibly introduced Academician Wang Guangji and Academician Shan Weiguang with the chief scientist system, according to the direction of enterprise development strategy to carry out scientific research work, and achieved fruitful results. In 2019, Spike Pharmaceuticals applied for 2 invention patents and obtained 5 patent authorizations, including 1 invention. By the end of 2019, Spike Pharmaceuticals had obtained a total of 37 patents (including 2 PCT patents), of which 28 were inventions. In recent years, in order to better integrate with the international market, Jianfeng Pharmaceutical has made a complete patent layout for the new drug DPT under development, and has applied for patent protection in multiple countries through the PCT application channel for core patents, and finally in the high-level United States. And Japan was authorized to lay a solid foundation for the product to enter these two overseas high-end markets. At the same time, around the core patent, applied for the preparation, crystal type patent and obtained the invention patent authorization 5. In addition, pharmaceutical companies have also developed patents for other varieties under research.
2020
07-31
Jianfeng Pharmaceuticals ranks among the top 50 creative enterprises in Jinhua
News from our newspaper April 26 is World Intellectual Property Day. Jinhua City released the list of "Top 50 Creative Enterprises" for the first time. Jianfeng Pharmaceutical Company entered the list and ranked second among the enterprises in Jinhua Development Zone. The selection of creative enterprises, the enterprise holds the effective invention patent as the main indicator. Over the years, Jianfeng Pharmaceutical Co., Ltd. has taken "intellectual property rights help enterprise development, and scientific and technological innovation creates a century-old peak" as the company's intellectual property policy. It has actively cooperated with China Pharmaceutical University, Sichuan Institute of Antibiotic Industry, Zhejiang University of Technology, Xiamen University and other units to build a scientific research and innovation platform integrating production, learning and research, and flexibly introduced Academician Wang Guangji and Academician Shan Weiguang with the chief scientist system, according to the direction of enterprise development strategy to carry out scientific research work, and achieved fruitful results. In 2019, Spike Pharmaceuticals applied for 2 invention patents and obtained 5 patent authorizations, including 1 invention. By the end of 2019, Spike Pharmaceuticals had obtained a total of 37 patents (including 2 PCT patents), of which 28 were inventions. In recent years, in order to better integrate with the international market, Jianfeng Pharmaceutical has made a complete patent layout for the new drug DPT under development, and has applied for patent protection in multiple countries through the PCT application channel for core patents, and finally in the high-level United States. And Japan was authorized to lay a solid foundation for the product to enter these two overseas high-end markets. At the same time, around the core patent, applied for the preparation, crystal type patent and obtained the invention patent authorization 5. In addition, pharmaceutical companies have also developed patents for other varieties under research.
2020
07-30
Jianfeng Pharmaceuticals ranks among the top 50 creative enterprises in Jinhua
News from our newspaper April 26 is World Intellectual Property Day. Jinhua City released the list of "Top 50 Creative Enterprises" for the first time. Jianfeng Pharmaceutical Company entered the list and ranked second among the enterprises in Jinhua Development Zone. The selection of creative enterprises, the enterprise holds the effective invention patent as the main indicator. Over the years, Jianfeng Pharmaceutical Co., Ltd. has taken "intellectual property rights help enterprise development, and scientific and technological innovation creates a century-old peak" as the company's intellectual property policy. It has actively cooperated with China Pharmaceutical University, Sichuan Institute of Antibiotic Industry, Zhejiang University of Technology, Xiamen University and other units to build a scientific research and innovation platform integrating production, learning and research, and flexibly introduced Academician Wang Guangji and Academician Shan Weiguang with the chief scientist system, according to the direction of enterprise development strategy to carry out scientific research work, and achieved fruitful results. In 2019, Spike Pharmaceuticals applied for 2 invention patents and obtained 5 patent authorizations, including 1 invention. By the end of 2019, Spike Pharmaceuticals had obtained a total of 37 patents (including 2 PCT patents), of which 28 were inventions. In recent years, in order to better integrate with the international market, Jianfeng Pharmaceutical has made a complete patent layout for the new drug DPT under development, and has applied for patent protection in multiple countries through the PCT application channel for core patents, and finally in the high-level United States. And Japan was authorized to lay a solid foundation for the product to enter these two overseas high-end markets. At the same time, around the core patent, applied for the preparation, crystal type patent and obtained the invention patent authorization 5. In addition, pharmaceutical companies have also developed patents for other varieties under research.
2020
07-22
On April 24, Jiang Xiaomeng, chairman of the group company, presided over the 14th meeting of the 10th board of directors of the company, and deliberated and passed 14 related reports and motions such as the 2019 annual board of directors report, the 2019 general manager business report and the 2019 annual report. The general manager's report pointed out that 2019 is the first year of the implementation of the group's new five-year strategic development plan (2019-2023) and the new three-year business plan (2019-2021) for each business sector. the management team has carried out various operation and management work in an orderly manner around the general policy of "innovation and reform, integration and promotion, scientific layout and steady development", and has better completed the business objectives set by the board of directors at the beginning of the year. In the whole year, the company achieved a total operating income of 3.548 billion billion yuan, an increase of 5.51 percent over the same period last year; net profit attributable to shareholders was 0.725 billion billion yuan, with earnings per share reaching 2.11 billion yuan, an increase of 23.14 percent over the same period last year, a record high; total assets at the end of the year were 5.475 billion billion yuan, an increase of 11.71 percent over the same period last year; and net assets attributable to shareholders were 3.789 billion billion yuan, an increase of 19.81 percent. During the reporting period, the company's two main businesses have achieved great development, benefiting from the further promotion of supply-side structural reform, the overall operation of the cement industry in 2019 is stable, and the industry benefits are further improved. During the reporting period, the company made new progress in the construction of cement projects, completed the acquisition, capital increase and name change of Guizhou Mingchuan (Guizhou Huangping Jianfeng Cement Co., Ltd.), and continued to invest in the construction of its new dry cement production line with a daily output of 4500 tons of clinker.
2020
07-31